Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18334882 | 0.74 | IDUA (0.33) | IDUA | |
| SCHEMBL21097605 | 0.74 | APLNR (0.33) | IDUA | |
| SCHEMBL29740164 | 0.71 | IDUA (0.33) | IDUA | |
| SCHEMBL13858344 | 0.71 | IDUA (0.33) | IDUA | |
| SCHEMBL16750226 | 0.69 | SUCNR1 (0.35) | IDUA | |
| SCHEMBL9156079 | 0.66 | KAT2A (0.33) | — | |
| SCHEMBL23247975 | 0.65 | IDUA (0.38) | IDUA | |
| SCHEMBL9507606 | 0.65 | IDUA (0.38) | IDUA | |
| SCHEMBL5436141 | 0.65 | AKT1 (0.34) | — | |
| SCHEMBL1537221 | 0.65 | AKT1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | MIRUM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SATIOGEN PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207260-A1 | METHODS FOR TREATING CHOLESTASIS | SLC10A1, SLC10A2, NR1H4 | IDUA 1398/4885 |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SLC10A1, SLC10A2, ABCB11 | IDUA 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.